Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
8.31
-0.05 (-0.60%)
Nov 16, 2026, 4:00 PM EST - Market closed
ARCT Revenue
Arcturus Therapeutics Holdings had revenue of $18.30M in the quarter ending September 30, 2026, with 6.68% growth. This brings the company's total for the last twelve months to $30.51M, down -68.74% year-over-year. In the year 2025, Arcturus Therapeutics Holdings had annual revenue of $82.03M, down -46.14%. That makes Arcturus Therapeutics Holdings the 31,282nd largest company in the world by revenue and 4,126th in the United States.
Revenue (ttm)
$30.51M
Revenue Growth
-68.74%
P/S Ratio
7.85
Revenue / Employee
$274,892
Employees
111
Market Cap
239.52M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 82.03M | -70.28M | -46.14% |
| Dec 31, 2024 | 152.31M | -14.49M | -8.69% |
| Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
| Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
| Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
| Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
| Dec 31, 2019 | 20.79M | 5.04M | 31.97% |
| Dec 31, 2018 | 15.75M | 2.76M | 21.20% |
| Dec 31, 2017 | 13.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 229.28M |
| Protalix BioTherapeutics | 84.69M |
| Bicycle Therapeutics | 83.53M |
| Q32 Bio | 53.74M |
| Camp4 Therapeutics | 5.32M |
| Inovio Pharmaceuticals | 298.90K |
ARCT News
- 16 hours ago - Arcturus Therapeutics price target lowered to $40 from $41 at Roth Capital - TheFly
- 19 hours ago - Arcturus Therapeutics announces $50M investment by Meiji Seika - TheFly
- 19 hours ago - Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration - Business Wire
- 7 days ago - Arcturus Therapeutics Holdings Transcript: Guggenheim 3rd Annual Healthcare Innovation Conference - Transcripts
- 11 days ago - Arcturus Therapeutics Holdings Earnings Call Transcript: Q3 2026 - Transcripts
- 11 days ago - Arcturus Therapeutics Holdings Earnings release: Q3 2026 - Filings
- 11 days ago - Arcturus Therapeutics Holdings Quarterly report: Q3 2026 - Filings
- 11 days ago - Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline Progress - Business Wire